Intermediate Risk MDS with Dr. Swapna Thota
What does the diagnosis, Intermediate-Risk MDS mean? Learn from Myelodysplastic Syndromes expert, Dr. Swapna Thota, in this recording.
AAMDSIF is proud to announce the launch of our new website! You'll now find everything quickly and easily.
What does the diagnosis, Intermediate-Risk MDS mean? Learn from Myelodysplastic Syndromes expert, Dr. Swapna Thota, in this recording.
Dr. Joshua Zeidner explains why it is critical for patients to receive an accurate diagnosis for MDS, or Myelodysplastic Syndromes. He describes the steps to determine the presence of the disease, and also discusses some of the treatments available.
Dr. Norkin explains why and how patients with PNH can develop blood clots, as well as prevention and treatment.
Dr. Timothy Pardee discusses treatments for AML, or Acute Myeloid Leukemia, occurring in older adults.
Dr. Allyson Pishko shares the latest advances in the treatment of PNH, or Paroxysmal Nocturnal Hemoglobinuria.
Dr. Nandita Khera discusses why and when transplants can be recommended for older patients in this podcast episode.
Dr. Rory Shallis discusses a variety of current treatments for MDS, or Myelodysplastic Syndromes
Dr. Jacqueline Garcia discusses the use of hypomenthylating agents.
Key Points
Itacitinib monotherapy is as effective as systemic corticosteroids for the treatment of low risk acute GVHD.
Itacitinib monotherapy resulted in fewer serious infections compared to systemic corticosteroids.